Neal D. Shore, MD

Neal D. Shore, MD

Carolina Urologic Research Center

Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS, graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center and is the Chief Medical Officer, Strategic Growth and Pharmacy, GenesisCare, US.

Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored or coauthored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, Maple Tree Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy for the Large Urology Group Practice Association (LUGPA) Specialty Network. He also co-chairs the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP and World Journal of Urology, and he also serves as an editor of Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.

Disclosures:

Dr. Shore has the following disclosures:
- Advisory Committee Member: Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Merck, Pfizer, Sanofi, Tolmar
- Consultant: Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Merck, Pfizer, Sanofi, Tolmar

Talks by Neal D. Shore, MD

GRU Challenging Case: Androgen Deprivation Therapy

GRU Challenging Case: Androgen Deprivation Therapy

Posted by | Jul 2020

Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center, discusses the physiological and economic factors impacting the ADT selection process. He particularly emphasizes the impact of the current volume-based and economically incentivized model of treatment and how this can restrict urologists. He also discusses the physiological impacts of drug-drug interactions, alternate modes of administration, and the complex prospect of an oral alternative.

Read More
29MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate Biopsies

29MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate Biopsies

Posted by | Jun 2020

Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center and a urologist at the Atlantic Urology Clinics in Myrtle Beach, South Carolina, discusses the use of a 29MHz micro-ultrasound (MUS) in targeting suspicious regions during prostate biopsy. He explains how the MUS can expedite time to diagnosis through improved real-time visualization, notes the short 15-case learning curve of the device, and discusses studies demonstrating improved negative predictive value and sensitivity of MUS compared to MRI.

Read More
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer

HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer

Posted by | Jun 2020

Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center, presents the key aspects of the HERO phase 3 trial. The Hero trial looked at Relugolix, an oral GnRH receptor antagonist, versus Leuprolide Acetate for the treatment of advanced prostate cancer. Following this in an interview with Celestia S. Higano, MD, section editor of the ADT Next Generation Learning Center on Grand Rounds in Urology, about the study’s findings, and the implications that this exciting new development in prostate cancer treatment could have in the field of urology.

Read More
Prostate Imaging and Biopsy Controversies

Prostate Imaging and Biopsy Controversies

Posted by | May 2020

Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center, discusses the evolution of transrectal (TR) versus transperineal (TP) prostate biopsy, and compares the efficacy of multi-parametric MRI (mpMRI) versus next generation micro-ultrasound. He goes on to discuss several studies that review the complication rates of TR and TP biopsy, differences in their diagnostic sensitivity, and various procedural techniques associated with TP prostate biopsy. Dr. Shore then examines several landmark studies that summarize the clinical utility of mpMRI and micro-ultrasound and describes the strengths and weaknesses associated with each technique. He concludes by discussing preliminary data comparing the diagnostic performance of micro-ultrasound to mpMRI.

Read More
Preserving Independent Urology: LUGPA’s First Decade

Preserving Independent Urology: LUGPA’s First Decade

Posted by | Dec 2019

Neal D. Shore, MD and E. David Crawford, MD, discuss Dr. Shore’s recent MedReview article (excerpted and linked below) on the ways in which the Large Urology Group Practice Association, or LUGPA, has advocated on behalf of community urology physicians and patients over the last ten years. Dr. Shore discusses how the organization has fought for legislative change to improve patient access to physicians of their choice, worked to ensure the availability of the latest in imaging and diagnostic technology for community urologists, and, in the face of increased consolidation of the healthcare industry, promoted value-based healthcare above volume-based healthcare, concluding in the article that:

“Eleven years after LUGPA’s inception, its passion and commitment to protecting and preserving the independent practice of urology remain stronger than ever. Without LUGPA, there would be far fewer opportunities for independent urology practices, fair-balanced education, networking, or external benchmarking than we have today. LUGPA groups have been able to integrate essential urologic services at a lower cost than their hospital competitors. Many of our member practices have become urologic centers of excellence with subspecialty lines of service and innovative, cost-effective pathways that optimize patient outcomes.

“Innovation springs from independence, not bureaucracy. Independent practitioners have the freedom and flexibility to share decision-making with their patients and to rapidly implement, test, and adapt new diagnostics, therapeutics, and pathways. Backed by a robust organization such as LUGPA, independent urologists can implement innovative approaches that significantly improve the health of their patients and the sustainability of their practices. Such nimbleness is especially crucial given the current rapid pace of change in urology. Aligning the interests of patients, providers, and payers by promoting value-based care at independent, integrated physician practices is LUGPA’s ongoing mission; our rallying cry should be to continue that mission in an open, transparent, and inclusive fashion.” (Used with permission from MedReviews / Reviews in Urology, which holds the copyright to the original article.)

Read More

Join the GRU Community

- Why Join? -